Real-World Data Show that Single-Agent Cabozantinib May Become the Second-Line Treatment of Metastatic Renal Cell Carcinoma
New evidence suggests no benefit in adding immune checkpoint inhibitors to cabozantinib for patients with metastatic renal cell carcinoma who have progressed after prior immune checkpoint inhibitors therapy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in